Vol. 46 (x): 2020 May 5.[Ahead of print]
Marcio Augusto Averbeck 1, Jorge Moreno-Palacios 2, Alejandro Aparicio 3
1 Coordenador de Neurourologia, Unidade de Videourodinâmica, Moinhos de Vento Hospital, Porto Alegre, RS, Brasil; 2 Servicio de Urologia, Unidad de Alta Especialidad Centro Médico Nacional Siglo XXI, IMSS, México, MX; 3 Clinica del Country, Bogota, Colombia
Purpose: To review current literature regarding sacral neuromodulation (SNM) for neurogenic lower urinary tract dysfunction (NLUTD) focused on indications, barriers and latest technological developments.
Material and Methods: A PubMed database search was performed in April 2020, focusing on SNM and various neuro-urological conditions.
Results: SNM has been increasingly indicated for lower urinary tract dysfunction (LUTD) in neuro-urological patients. Most studies are cases series with several methodological limitations and limited follow-up, lacking standardized definition for SNM clinical success. Most series focused on neurogenic overactive bladder in spinal cord injured (incomplete lesions) and multiple sclerosis patients. Barriers for applying this therapy in neurogenic LUTD were mainly related to magnetic resonance imaging incompatibility, size of the implantable pulse generator (IPG), and battery depletion. Newer technological advances have been made to address these limitations and will be widely available in the near future.
Conclusions: SNM seems a promising therapy for neurogenic LUTD in carefully selected patients with incomplete lesions. Further studies are still needed to define which subgroups of neurological patients benefit the most from this minimally invasive technique.
Keywords: Sacral neuromodulation, neurogenic bladder, lower urinary tract symptoms